Brief: Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP
23/12/2025 13:12
Dec 23 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026 Source text: ID:nGNX52SsCL Further company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences